Nothing new here

Strong revenue growth, adding more capacity, increasing revenue guidance all in an expanding market what more could anyone want. Nothing if you’re a Dexcom investor as this company continues to methodically build their already strong business. As well as the company is doing it would be foolish to ignore what could derail this runway freight train. Here are just some of the possible items that could push this train off the rails.

Abbott Goes Nuclear

Abbott has already made it very clear they will be the value option in CGM. However Dexcom is beginning to invade their turf on . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.